NeuroBo (NASDAQ:NRBO) Soars on Licensing Deal
Market News

NeuroBo (NASDAQ:NRBO) Soars on Licensing Deal

Shares of NeuroBo Pharmaceuticals (NASDAQ:NRBO) are skyrocketing today after the company entered into an exclusive licensing agreement with Dong-A to develop and commercialize two candidates, DA-1241 and DA-1726, for the treatment of non-alcoholic steatohepatitis (NASH), obesity and type 2 diabetes.

Under the deal, NRBO will be responsible for the global development as well as regulatory and commercial activities (except for certain Asian-Pacific geographies). Dong-A will provide clinical and initial commercial supplies from its Korea facility.

The development comes fresh on the heels of NRBO’s recent 1-for-30 reverse stock split.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
RUT
Russell 2000
TNX
10-Yr-Bond
Bitcoin

Popular Articles